StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$69.99−0.90 (-1.27%)

Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –

Earnings

ANI Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 26, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$290.80M
+27.7% on a year earlier
adjusted non-GAAP diluted earnings per share, Q3 FY2026
$2.70
$2.04 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of ANI Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 26, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$290.80M+27.7%$1.51$2.70Release
Q2 FY2026ended Jun 30, 2026Aug 7, 2026before the open$266.00M+25.8%$1.05$2.21Release
Q1 FY2026ended Mar 31, 2026May 8, 2026before the open$237.50M+20.5%$1.28$2.05Release
Q4 FY2025ended Dec 31, 2025Feb 27, 2026before the open$247.10M+29.6%$1.18$2.33Release
Q3 FY2025ended Sep 30, 2025Nov 7, 2025before the open$227.80M+53.6%$1.13$2.04Release
Q2 FY2025ended Jun 30, 2025Aug 8, 2025before the open$211.40M+53.2%$0.36$1.80Release
Q1 FY2025ended Mar 31, 2025May 9, 2025before the open$197.10M+43.4%$0.69$1.70Release
Q4 FY2024ended Dec 31, 2024Feb 28, 2025before the open$190.60M+44.7%-$0.55$1.63Release
Q3 FY2024ended Sep 30, 2024Nov 8, 2024before the open$148.30M+12.5%-$1.27$1.34Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open$138.00M+18.5%-$0.14$1.02Release
Q1 FY2024ended Mar 31, 2024May 10, 2024before the open$137.40M+28.7%$0.82$1.21Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

ANI Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Cortrophin Gel net revenue growthFY2026+50% – +55%–RaisedAug 7, 2026
ILUVIEN Net RevenueFY2026$80.00M – $85.00M$540.00M – $575.00MLoweredNov 5, 2026
total net revenueFY2026$1.08B – $1.14B$1.08B – $1.14BReaffirmedAug 7, 2026
adjusted non-GAAP gross marginnon-GAAPFY202659.9% – 60.9%59.9% – 60.9%ReaffirmedAug 7, 2026
total company adjusted non-GAAP gross marginnon-GAAPFY202660.3% – 61%59.3% – 60.3%RaisedNov 5, 2026
adjusted non-GAAP EBITDAnon-GAAPFY2026$285.00M – $300.00M$285.00M – $300.00MReaffirmedAug 7, 2026
Adjusted Non-GAAP EBITDAnon-GAAPFY2026$290.00M – $300.00M$275.00M – $290.00MRaisedNov 5, 2026
Adjusted Non-GAAP EBITDA Growthnon-GAAPFY2026+24% – +31%–NewAug 7, 2026
Adjusted Non-GAAP Diluted EPSnon-GAAPFY2026$9.37 – $9.71$8.83 – $9.34RaisedNov 5, 2026
Adjusted Non-GAAP Diluted EPSnon-GAAPFY2026$9.19 – $9.69$9.19 – $9.69ReaffirmedAug 7, 2026
Adjusted Non-GAAP Diluted EPS Growthnon-GAAPFY2026+16% – +23%–NewAug 7, 2026
annual U.S. GAAP effective tax rateGAAPFY202626% – 28%26% – 28%ReaffirmedAug 7, 2026
annual U.S. GAAP effective tax rateGAAPFY202626% – 28%–NewFeb 27, 2026
Cortrophin Gel net revenueFY2026$540.00M – $575.00M–NewMay 8, 2026
ILUVIEN Net RevenueFY2026$78.00M – $83.00M–LoweredMay 8, 2026
shares outstandingnon-GAAPFY202621.5 – 21.8–NewMay 8, 2026
shares outstanding for the purpose of calculating full year adjusted non-GAAP diluted EPSnon-GAAPFY202621.5 – 21.8–ReaffirmedAug 7, 2026

Guidance vs results

The last range ANI Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025adjusted non-GAAP diluted earnings per share$7.37 – $7.64$7.87Σ4QAbove range
FY2025Revenue$73.00M – $77.00M$883.40MΣ4QAbove range
FY2025Revenue growth+75% – +78%+43.81%Σ4QBelow range

Guidance history

Every forecast ANI Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Adjusted Non-GAAP EBITDAFY2026$290.00M – $300.00MRaised
Nov 5, 2026Adjusted Non-GAAP Diluted EPSFY2026$9.37 – $9.71Raised
Nov 5, 2026total company adjusted non-GAAP gross marginFY202660.3% – 61%Raised
Nov 5, 2026ILUVIEN Net RevenueFY2026$80.00M – $85.00MLowered
Nov 5, 2026Cortrophin Gel Net RevenueFY2026$480.00M – $500.00MLowered
Nov 5, 2026Net Revenue (Total Company)FY2026$1.09B – $1.13BRaised
Aug 7, 2026Adjusted Non-GAAP EBITDA GrowthFY2026+24% – +31%New
Aug 7, 2026adjusted non-GAAP EBITDAFY2026$285.00M – $300.00MReaffirmed
Aug 7, 2026Adjusted Non-GAAP Diluted EPSFY2026$9.19 – $9.69Reaffirmed
Aug 7, 2026Adjusted Non-GAAP Diluted EPS GrowthFY2026+16% – +23%New
Aug 7, 2026adjusted non-GAAP gross marginFY202659.9% – 60.9%Reaffirmed
Aug 7, 2026shares outstanding for the purpose of calculating full year adjusted non-GAAP diluted EPSFY202621.5 – 21.8Reaffirmed
Aug 7, 2026annual U.S. GAAP effective tax rateFY202626% – 28%Reaffirmed
Aug 7, 2026Cortrophin Gel net revenue growthFY2026+50% – +55%Raised
Aug 7, 2026ILUVIEN Net Revenue GrowthFY2026+4% – +11%Lowered
Aug 7, 2026total net revenueFY2026$1.08B – $1.14BReaffirmed
Aug 7, 2026Cortrophin Gel net revenueFY2026$520.00M – $540.00MLowered
Aug 7, 2026ILUVIEN Net RevenueFY2026$78.00M – $83.00MLowered
Aug 7, 2026Net Revenue (Total Company) GrowthFY2026+22% – +29%New
May 8, 2026adjusted non-GAAP EBITDAFY2026$285.00M – $300.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases ANI Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. News
  3. News
  4. News
  5. Results
  6. Results
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?